IIM
BEAM icon

IFC & Insurance Marketing’s Beam Therapeutics BEAM Stock Holding History

IFC & Insurance Marketing’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,500
Closed -$69K – 125
2025
Q4 		$69K Buy
+2,500
New +$63.8K 0.07% 140

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

IFC & Insurance Marketing's BEAM Position: Q1 2026 in Review

IFC & Insurance Marketing sold out of Beam Therapeutics (BEAM) in Q1 2026, closing a stake of 2,500 shares — an estimated $69K sold.

IFC & Insurance Marketing first reported a position in BEAM in Q4 2025 and held it in 1 quarter. The position peaked at $69K in Q4 2025. 253 funds tracked by Wall St. Rank hold BEAM as of Q1 2026.

  • IFC & Insurance Marketing reported no remaining Beam Therapeutics position as of Q1 2026 after selling out during the quarter.
  • IFC & Insurance Marketing sold 2,500 Beam Therapeutics shares in Q1 2026, an estimated $69K.
  • IFC & Insurance Marketing first reported a position in Beam Therapeutics in Q4 2025 and held it in 1 quarter.
  • IFC & Insurance Marketing's Beam Therapeutics position peaked at $69K in Q4 2025.
  • 253 funds tracked by Wall St. Rank held Beam Therapeutics as of Q1 2026.

Based on IFC & Insurance Marketing's 13F filing for Q1 2026, filed 17 Apr 2026.